TAS-CC4 Study
Ontology highlight
ABSTRACT: Interventions: TAS-102: 35mg/m2 given orally twice daily on days 1-5 and 15-19 in a 28-day cycle.
Bevacizumab: 5mg/kg given intravenously in a 2-week cycle
Primary outcome(s): progression free survival
Study Design: single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose
DISEASE(S): Colorectal Cancer
PROVIDER: 2614211 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA